Drugs / tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine
tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02479230 | Jul 2015 → Oct 2019 | breast cancer, metastatic neoplasm | Joseph Baar, MD, PhD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02479230 ↗ |
| Action | Activate | “may help activate the immune system against stromal cells” NCT02479230 ↗ |
| Modality | Vaccine | “dendritic cell vaccine” NCT02479230 ↗ |